Canada markets closed

Hemostemix Inc. (HEM.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.01000.0000 (0.00%)
At close: 11:16AM EDT
Full screen
Previous Close0.0100
Open0.0050
Bid0.0050 x 0
Ask0.0100 x 0
Day's Range0.0050 - 0.0100
52 Week Range0.0050 - 0.0350
Volume240,000
Avg. Volume209,438
Market Cap7.568M
Beta (5Y Monthly)0.89
PE Ratio (TTM)N/A
EPS (TTM)-0.0080
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Hemostemix Files Its Unaudited Condensed Consolidated Interim Financial Statements and Management Discussion and Analysis for the Three Months Ended March 31, 2020
    Newsfile

    Hemostemix Files Its Unaudited Condensed Consolidated Interim Financial Statements and Management Discussion and Analysis for the Three Months Ended March 31, 2020

    Calgary, Alberta--(Newsfile Corp. - July 13, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") today filed on SEDAR its unaudited Condensed Consolidated Interim Financial Statements and Management Discussion and Analysis for the quarter ending March 31, 2020 and for the comparable period ending March 31, 2019.ABOUT HEMOSTEMIX Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and ...

  • Hemostemix Files Its Audited Annual Financial Statements and Management Discussion and Analysis for the Period Ending December 31, 2019
    Newsfile

    Hemostemix Files Its Audited Annual Financial Statements and Management Discussion and Analysis for the Period Ending December 31, 2019

    Calgary, Alberta--(Newsfile Corp. - July 10, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") today filed on SEDAR its audited Financial Statements and Management Discussion and Analysis for the annual period and fourth quarter ending December 31, 2019 and for the comparable periods ending December 31, 2018.ABOUT HEMOSTEMIX Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the Company ...

  • Hemostemix Announces Closing of Private Placement
    Newsfile

    Hemostemix Announces Closing of Private Placement

    Calgary, Alberta--(Newsfile Corp. - July 9, 2020) -  Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces it has closed its previously announced non-brokered private placement of units ("Units") for gross proceeds of $266,500(the "Offering"). The Offering consisted of the issuance of an aggregate of 26,650,000 Units at a price of $0.01 per Unit. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common ...